Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
Top Cited Papers
- 21 February 2019
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 76 (4), 452-458
- https://doi.org/10.1016/j.eururo.2019.02.002
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health Cancer Center (P30 CA006973, P30 CA015704)
- Pacific Northwest Prostate Cancer SPORE (CA097186)
- Department of Defense (W81XWH-16-PCRP-CCRSA)
- Patrick C. Walsh Research Fund
- Institute for Prostate Cancer Research and Prostate Cancer Foundation Awards
This publication has 16 references indexed in Scilit:
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerCell, 2018
- The long tail of oncogenic drivers in prostate cancerNature Genetics, 2018
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerCancer Discovery, 2018
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and EnzalutamideEuropean Urology, 2018
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate CancerEuropean Urology, 2017
- Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate TumorsAmerican Journal of Human Genetics, 2016
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyClinical Cancer Research, 2015
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationJournal of Clinical Oncology, 2015
- The DNA Damage Response: Ten Years AfterMolecular Cell, 2007
- The relationship between the roles of BRCA genes in DNA repair and cancer predispositionTrends in Molecular Medicine, 2002